SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) May 2, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On May 2, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that there are no unusual events that have
taken place in the Company, and there is no real material reason
for the Company's stock to drop.
The Company further stated that the in-home testing in
the FDA protocol for the Diasensorr 1000 noninvasive glucose
sensor for diabetics is going as planned, and additional
financing has been arranged which will enable the Company to take
its products into the market, especially those involved with the
recently formed Chinese joint venture.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: May 2, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL SAYS NO MATERIAL REASON FOR STOCK DROP
Pittsburgh, PA - May 2, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that there are no unusual events
that have taken place in the Company, and there is no real
material reason for the Company's stock to drop.
Fred E. Cooper, chief executive officer of Biocontrol,
stated, "Today's drop in stock is simply a result of rumors that
are out there on the streets promoted by those who are taking a
short position in our stock. This has been going on for years,
and other shareholders unfortunately seem to follow these kinds
of trends and rumors."
The Company further stated that the in-home testing in the
FDA protocol for the Diasensorr 1000 noninvasive glucose sensor
for diabetics is going as planned, and additional financing has
been arranged which will enable the Company to take its products
into the market, especially those involved with the recently
formed Chinese joint venture.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
